Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Umbralisib with ibrutinib in patients with R/R CLL or MCL

Matthew Davids • 11 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Umbralisib

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, updates us on long-term results of a Phase Ib study investigating ibrutinib with umbralisib, a PI3Kdelta inhibitor, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Davids

Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
Does MRD-guided therapy have potential in CLL?
1:01
Does MRD-guided therapy have potential in CLL?
Matthew Davids • 12 Jun 2026
Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
1:11
Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
Matthew Davids • 12 Jun 2026
GLORA trial: lisaftoclax plus BTKi in previously treated CLL
1:18
GLORA trial: lisaftoclax plus BTKi in previously treated CLL
Matthew Davids • 12 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals